SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Research and Markets: Heplisav: 1018 ISS Immunostimulatory Oligonucleotide with HBsAg (Prophylactic Hepatitis B Virus Vaccines) - Global Forecast and Market Analysis to 2022
[April 23, 2014]

Research and Markets: Heplisav: 1018 ISS Immunostimulatory Oligonucleotide with HBsAg (Prophylactic Hepatitis B Virus Vaccines) - Global Forecast and Market Analysis to 2022


DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/l8hslp/heplisav) has announced the addition of the "Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022" report to their offering.

Heplisav [Hepatitis B vaccine, 1018 ISS immunostimulatory oligonucleotide with HBsAg (HBsAg-1018)] is Dynavax Technologies' adjuvanted pipeline vaccine candidate that guards adults against acute and chronic infections caused by all known strains of HBV, with a particular emphasis on protecting adults that have failed to achieve seroconversion from the currently licensed HBV vaccines. With Heplisav, Dynavax hopes to address a key clinical unmet need in the treatment landscape while simultaneously improving HBV vaccination coverage in adults.

Scope

  • Overview of Hepatitis B disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Heplisav including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Heplisav for top eight countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, UK, Japan and Canada.

Key Topics Covered:


1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Overview

3.2 Etiology and Pathophysiology

3.3 Symptoms

3.4 Prognosis (News - Alert)

4 Vaccination Recommendations and Coverage Rates

5 Competitive Assessment

5.1 Overview

5.2 Strategic Competitor Assessment

6 Opportunity and Unmet Need

6.1 Overview

6.2 Increased Vaccine Immunogenicity

6.3 Increased Vaccination Coverage Rates

6.4 Increased Patient Awareness

6.5 Improved Physician Education

6.6 More Cost-Effective Vaccines

7 Pipeline Assessment

8 Heplisav

8.1 Overview

8.2 Immunogenicity

8.3 Safety

8.4 Dosing and Formulation

8.5 Potential Clinical Positioning

8.6 Potential Commercial Positioning

8.7 Pricing and Reimbursement

8.8 SWOT Analysis

8.9 Forecast

9 Appendix

For more information visit http://www.researchandmarkets.com/research/l8hslp/heplisav


[ Back To TMCnet.com's Homepage ]






Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2017 Technology Marketing Corporation. All rights reserved | Privacy Policy